Biotechnology company focused on developing therapies for severe allergic reactions.
Artivion, Inc., formerly known as CryoLife, Inc., is a global leader in manufacturing, processing, and distributing medical devices and implantable human tissues. Established in 1984 and headquartered in Kennesaw, Georgia, the company specializes in a diverse array of innovative healthcare solutions.
Artivion's product portfolio includes BioGlue, a polymer derived from bovine blood proteins used in cardiac, vascular, neurologic, and pulmonary procedures. The company also provides cardiac preservation services, PhotoFix pericardial patches, and advanced systems such as E-vita Open Plus and E-vita Open Neo for cardiovascular interventions.
Innovative engineering solutions like E-xtra and E-nside address complex aortic vascular diseases, while products such as E-vita THORACIC 3G and E-nya offer minimally invasive options for thoracic aortic aneurysms and other lesions of the descending aorta. Additionally, Artivion manufactures E-ventus BX for renal and pelvic artery treatments, E-liac for iliac artery aneurysms, and E-tegra for abdominal aortic aneurysms.
The company's comprehensive offerings extend to synthetic vascular grafts, PerClot hemostats, cardiac laser therapy products, and CryoVein and CryoArtery preservation services. Artivion also provides On-X prosthdetic heart valves, CarbonAid CO2 diffusion catheters, Chord-X ePTFE sutures, and medical dissection stents to healthcare providers worldwide. Through its dedication to innovation and quality, Artivion continues to advance medical technology and enhance patient care globally.